You have accessJournal of UrologyProstate Cancer: Markers I1 Apr 2017MP28-07 AN AUTOMATED-MICROCAPILLARY ELECTROPHORESIS-BASED IMMUNOASSAY SYSTEM MAY IMPROVE DIAGNOSTIC ACCURACY OF PROSTATE CANCER AND BE A GOOD INDICATOR OF GLEASON SCORE Tomokazu Ishikawa, Tohru Yoneyama, Yuki Tobisawa, Shingo Hatakeyama, Tatsuo Kurosawa, Kenji Nakamura, Takuya Koie, Yasuhiro Hashimoto, and Chikara Ohyama Tomokazu IshikawaTomokazu Ishikawa More articles by this author , Tohru YoneyamaTohru Yoneyama More articles by this author , Yuki TobisawaYuki Tobisawa More articles by this author , Shingo HatakeyamaShingo Hatakeyama More articles by this author , Tatsuo KurosawaTatsuo Kurosawa More articles by this author , Kenji NakamuraKenji Nakamura More articles by this author , Takuya KoieTakuya Koie More articles by this author , Yasuhiro HashimotoYasuhiro Hashimoto More articles by this author , and Chikara OhyamaChikara Ohyama More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2017.02.820AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Lack of specificity in PSA test for early detection of prostate cancer (PCa) is one of the major issues all over the world. Therefore, the development of novel assay system with improved specificity is urgently needed. We identified PCa-associated aberrant glycosylation of PSA (S2,3PSA) and developed an automated-microcapillary electrophoresis-based immunoassay system (μTAS method). Furthermore, we successfully applied this assay system for clinical setting. METHODS S2,3PSA was clearly differentiated by the lectin reactivity to recognize aberrant glycosylation on free PSA (fPSA) and calculate the ratio (%) in the microfluidic separation channel with fPSA antibody-label conjugates. We measured %S2,3PSA by utilizing μTAS method with extremely shortened assay time (9 min) and evaluated the cutoff values in biopsy proven patient samples (103 with PCa and 50 with non-PCa) including PSA less than 20.0 ng/ml. Receiver operating characteristic (ROC) curves were used to evaluate diagnostic accuracy for %S2,3PSA in comparison with other methods. RESULTS %S2,3PSA of PCa was significantly higher than those of non-PCa (p < 0.0001) and the appropriate cutoff value was determined to be 40% of S2,3PSA ratio in terms of diagnostic accuracy. The area under the curve (AUC) for the detection of PCa with %S2,3PSA ratio was 0.851, which was significantly more effective than that with total PSA (AUC; 0.658). And also, good correlation in this assay with Gleason score after radical prostatectomy (pGS) was suggested for the discrimination of high risk PCa. Especially, high-risk PCa patients with GS≥4+3 could be separated by the S2,3PSA percentage cut off of 50%, achieving a high performance (AUC; 0.921). CONCLUSIONS Although the present study is still preliminary, these results suggest that the newly developed serum %S2,3PSA test may contribute improved diagnostic accuracy having good correlation with prostatectomy Gleason score. Additional validation studies are warranted. © 2017FiguresReferencesRelatedDetails Volume 197Issue 4SApril 2017Page: e340 Advertisement Copyright & Permissions© 2017MetricsAuthor Information Tomokazu Ishikawa More articles by this author Tohru Yoneyama More articles by this author Yuki Tobisawa More articles by this author Shingo Hatakeyama More articles by this author Tatsuo Kurosawa More articles by this author Kenji Nakamura More articles by this author Takuya Koie More articles by this author Yasuhiro Hashimoto More articles by this author Chikara Ohyama More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...
Read full abstract